Controversy Surrounds Texas Abortion Pill Ruling and Sparks Strong Reactions.
TL;DR Summary
More than 250 senior executives of pharmaceutical and biotech companies have condemned a ruling by a federal judge that invalidated the FDA's 23-year-old approval of the abortion pill mifepristone. The executives argue that the decision ignores scientific and legal precedent and creates uncertainty for the entire biopharma industry. They also said that pharmaceutical companies rely on the FDA's autonomy to bring products to market under a reliable regulatory process for drug evaluation and approval.
- Pfizer CEO and Other Drug Company Leaders Condemn Texas Abortion Pill Ruling The New York Times
- AOC doubles down on 'ignoring' abortion rule, Clarence Thomas impeachment: 'abuse of judicial overreach' Fox News
- WH 'disagrees strenuously' with Texas judge's decision on abortion pill MSNBC
- Opinion | I Worked at the F.D.A. The Abortion Pill Decision Is Dangerous. The New York Times
- Opinion | The Abortion Pill Ruling Is Bad Law, and the Biden Administration Should Fight It The New York Times
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
1 min
vs 2 min read
Condensed
74%
281 → 74 words
Want the full story? Read the original article
Read on The New York Times